Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00269477
Status:
COMPLETED
Last Update Posted:
2016-04-14
First Post:
2005-12-22
Brief Title:
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra or Menomune
Sponsor:
Sanofi Pasteur a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra or Menomune-ACYW-135 Five Years Earlier
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 15 to 23 years not yet 24 years who had been vaccinated five years previously in Study MTA02 and did not participate in Study MTA19 NCT 00777790 In addition the kinetics of the antibody response will be evaluated in a subset of these participants who will receive a booster dose of Menactra vaccine This will be compared to aged matched control subjects who have not been previously vaccinated with a meningococcal vaccine or had documented meningitis disease who will also receive a dose of Menactra vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None